Sandbox c7
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease. | It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 .<scene name='Sandbox_c7/Tacrine/1'>W84 and F330</scene> | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 .<scene name='Sandbox_c7/Tacrine/1'>W84 and F330</scene><ref>PMID8415649<<ref/> |
Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding | Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding | ||
Revision as of 13:25, 23 November 2010
|
1ACJ shows the crystal structure of Torpedo californica acetylcholinesterase (TcAChE) complexed with tacrine.
Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor.
It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease.
Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 .[1]
